GlassScriptPhysician profile
Aaron S Carlisle
NPI 1295713576
$2,871.90
in general payments reported to CMS, 2019-2025
27 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,398 · 2020: $255 · 2022: $218 · 2023: $432 · 2024: $138 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $738.27 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $619.42 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $188.79 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $187.15 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $187.07 | 2022-2025 | |
| Tris Pharma INC | $121.67 | 2019 | |
| Amgen INC. | $121.18 | 2019-2020 | |
| Minerva Surgical, INC | $99.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $78.22 | 2019 | |
| Pfizer INC. | $74.68 | 2019-2025 | |
| Amarin Pharma, INC. | $56.20 | 2019 | |
| Astellas Pharma US INC | $43.50 | 2019-2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $41.47 | 2019-2022 | |
| Allergan, INC. | $35.94 | 2019 | |
| Janssen Pharmaceuticals, INC | $32.75 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $32.22 | 2019-2020 | |
| Edwards Lifesciences Corporation | $28.32 | 2025 | Sapien 3 Ultra Resilia |
| Sanofi-Aventis U.S. LLC | $26.01 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.55 | 2019 | |
| Glaxosmithkline, LLC. | $24.40 | 2019-2020 | |
| Medtronic, INC. | $21.63 | 2023 | Intellis Adaptivestim |
| Corium, LLC | $20.33 | 2025 | Azstarys |
| Sanofi Pasteur INC. | $16.85 | 2019 | |
| Shire North American Group INC | $14.67 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.54 | 2025 | Jornay Pm |
| Genentech USA, INC. | $11.36 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Carlisle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.